id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S15842 R65223 |
Bromley (Levetiracetam) (Controls exposed to LTG), 2023 | Cognitive mean score ≤ 88 (below average performance of the cohort mean) - Bayley Scales of Infant and Toddler Development - At 24 months of age | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
3.86 [0.72;20.73] C excluded (control group) |
5/51 2/73 | 7 | 51 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S15843 R65236 |
Bromley (Levetiracetam) (Controls unexposed, sick), 2023 | Cognitive mean score ≤ 88 (below average performance of the cohort mean) - Bayley Scales of Infant and Toddler Development - At 24 months of age | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: No | 2.50 [0.46;13.55] C | 5/51 2/48 | 7 | 51 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9949 R53773 |
Videman (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2016 | Griffiths Mental Developmental Scale - General quotient (at the age of 7 months) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No extrapolated (cont. endpoint) |
0.73 [0.12;4.63] excluded (control group) |
-/7 -/8 | - | 7 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9951 R53774 |
Videman (Levetiracetam) (Controls unexposed, disease free), 2016 | Griffiths Mental Developmental Scale - General quotient (at the age of 7 months) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, disease free | Adjustment: No extrapolated (cont. endpoint) | 3.30 [0.79;13.90] | -/7 -/59 | - | 7 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S6762 R53772 |
Shallcross (Levetiracetam), 2011 | Overall development quotient (Griffiths scale) <84 | throughout pregnancy | prospective cohort | unexposed, disease free | Adjustment: No | 0.60 [0.18;1.97] C | 4/51 12/97 | 16 | 51 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 3 studies | 1.56 [0.51;4.80] | 23 | 109 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Levetiracetam) (Controls unexposed, sick; 2: Levetiracetam) (Controls unexposed, disease free; 3: Levetiracetam;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 9949, 15842